Abstract
LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.
| Original language | English |
|---|---|
| Pages (from-to) | 1336-1339 |
| Number of pages | 4 |
| Journal | American Review of Respiratory Disease |
| Volume | 140 |
| Issue number | 5 |
| State | Published - 1989 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
Cite this
A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. / Cloud, M. L.; Enas, G. C.; Kemp, J.; Platts-Mills, T.; Altman, L. C.; Townley, R.; Tinkelman, D.; King, T.; Middleton, E.; Sheffer, A. L.; McFadden, E. R.; Farlow, D. S.
In: American Review of Respiratory Disease, Vol. 140, No. 5, 1989, p. 1336-1339.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma
AU - Cloud, M. L.
AU - Enas, G. C.
AU - Kemp, J.
AU - Platts-Mills, T.
AU - Altman, L. C.
AU - Townley, R.
AU - Tinkelman, D.
AU - King, T.
AU - Middleton, E.
AU - Sheffer, A. L.
AU - McFadden, E. R.
AU - Farlow, D. S.
PY - 1989
Y1 - 1989
N2 - LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.
AB - LY171883 is a new selective LTD4/LTE4-receptor antagonist. To evaluate the efficacy of LY 171883, we studied 138 nonsmoking asthmatic patients, 18 to 65 yr old, in a double-blind, randomized block-design study. All patients were required to demonstrate a ≥15% increase in FEV1 after inhaled bronchodilator use and were then randomnly assigned to either LY171883 (600 mg) or placebo twice daily for 6 weeks. Assessment of efficacy was measured by inhaled metaproterenol use (mg/wk), symptoms, twice-daily peak expiratory flow, and weekly FEV1 measurements. LY171883-treated patients had improved FEV1 values upon completion of the treatment period compared with placebo recipients (p = 0.003). Metaproterenol use decreased in both groups, but treatment differences, though not statistically significant, favored LY171883 (p = 0.089). Of patients who used at least 23 mg/wk of metaproterenol (36 inhalations) at initiation of the study, those who received LY171883 used significantly less metaproterenol than those who received placebo (p = 0.007). LY171883 was well tolerated and reduced the need for a bronchodilator drug while improving pulmonary function. Results of this study support the hypothesis that leukotrienes LTD4 and/or LTE4 may be important in the pathogenesis of asthma in humans.
UR - http://www.scopus.com/inward/record.url?scp=0024474179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024474179&partnerID=8YFLogxK
M3 - Article
C2 - 2554766
AN - SCOPUS:0024474179
VL - 140
SP - 1336
EP - 1339
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
SN - 1073-449X
IS - 5
ER -